Pharmacological blockade of serotonin 5-HT7 receptor reverses working memory deficits in rats by normalizing cortical glutamate neurotransmission

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Bonaventure, Pascal ^a   Aluisio, Leah ^a   Shoblock, James ^a   Boggs, Jamin D ^a   Fraser, Ian C ^a   Lord, Brian ^a   Lovenberg, Timothy W ^a   Galici, Ruggero ^a,b  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [2 (4 METHYL 1 PIPERIDINYL)ETHYL] 1 PYRROLIDINESULFONYL]PHENOL; DIZOCILPINE; DOPAMINE; GLUTAMIC ACID; SCOPOLAMINE; SEROTONIN 7 RECEPTOR; DIZOCILPINE MALEATE; PHENOL DERIVATIVE; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOSENSOR; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; MALE; MAXIMUM PLASMA CONCENTRATION; MEMORY DISORDER; MICRODIALYSIS; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PREFRONTAL CORTEX; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; WORKING MEMORY; ANIMAL; BRAIN CORTEX; DRUG EFFECT; METABOLISM; SHORT TERM MEMORY; SPRAGUE DAWLEY RAT; SYNAPTIC TRANSMISSION;

ANIMALIA; RATTUS;

ANIMALS; CEREBRAL CORTEX; DIZOCILPINE MALEATE; GLUTAMIC ACID; MALE; MEMORY DISORDERS; MEMORY, SHORT-TERM; PHENOLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; SULFONAMIDES; SYNAPTIC TRANSMISSION;

EID: 79959289749     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020210     Document Type: Article

References (44)

1. Lovenberg TW, Baron BM, de Lecea L, Miller JD, Prosser RA, et al. (1993) A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms. Neuron 11: 449-458.
2. Harsing LG Jr, Prauda I, Barkoczy J, Matyus P, Juranyi Z, (2004) A 5-HT7 Heteroreceptor-Mediated Inhibition of [3H]Serotonin Release in Raphe Nuclei Slices of the Rat: Evidence for a Serotonergic-Glutamatergic Interaction. Neurochem Res 29: 1487-1497.
3. Hedlund PB, (2009) The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology 206: 345-354.
4. Leopoldo M, Lacivita E, Berardi F, Perrone R, Hedlund PB, (2011) Serotonin 5-HT7 receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disorders. PharmacolTher 129: 120-148.
5. Mnie-Filali O, Faure C, Lambas-Senas L, Mansari ME, Belblidia H, et al. (2011) Pharmacological Blockade of 5-HT(7) Receptors as a Putative Fast Acting Antidepressant Strategy. Neuropsychopharmacology.
6. Wesolowska A, Nikiforuk A, Stachowicz K, Tatarczynska E, (2006) Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression. Neuropharmacology 51: 578-586.
7. Bonaventure P, Kelly L, Aluisio L, Shelton J, Lord B, et al. (2007) Selective Blockade of 5-Hydroxytryptamine (5-HT)7 Receptors Enhances 5-HT Transmission, Antidepressant-Like Behavior, and Rapid Eye Movement Sleep Suppression Induced by Citalopram in Rodents. J PharmacolExpTher 321: 690-698.
8. Hedlund PB, Huitron-Resendiz S, Henriksen SJ, Sutcliffe JG, (2005) 5-HT7 Receptor Inhibition and Inactivation Induce Antidepressantlike Behavior and Sleep Pattern. Biol Psychiatry 58: 831-837.
9. Wesolowska A, Nikiforuk A, Stachowicz K, (2006) Potential anxiolytic and antidepressant effects of the selective 5-HT7 receptor antagonist SB 269970 after intrahippocampal administration to rats. Eur J of Pharmacol 553: 185-190.
10. Sarkisyan G, Roberts AJ, Hedlund PB, (2010) The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior. Behav Brain Res 209: 99-108.
11. Geyer MA, Ellenbroek B, (2003) Animal behavior models of the mechanisms underlying antipsychotic atypicality. Progress in Neuro-Psychopharmacology and Biol Psychiatry 27: 1071-1079.
12. Pouzet B, Didriksen M, Arnt J, (2002) Effects of the 5-HT(7) receptor antagonist SB-258741 in animal models for schizophrenia. PharmacolBiochemBehav 71: 655-665.
13. Galici R, Boggs JD, Miller KL, Bonaventure P, Atack JR, (2008) Effects of SB-269970, a 5-HT7 receptor antagonist, in mouse models predictive of antipsychotic-like activity. BehavPharmacol 19: 153-159.
14. Semenova S, Geyer MA, Sutcliffe JG, Markou A, Hedlund PB, (2008) Inactivation of the 5-HT7 Receptor Partially Blocks Phencyclidine-Induced Disruption of Prepulse Inhibition. Biol Psychiatry 63: 98-105.
15. Thomas DR, Hagan JJ, (2004) 5-HT7 receptors. Curr Drug Target CNS NeurolDisord 3: 81-90.
16. Cifariello A, Pompili A, Gasbarri A, (2008) 5-HT7 receptors in the modulation of cognitive processes. Behav Brain Res 195: 171-179.
17. Roberts C, Thomas DR, Bate ST, Kew JNC, (2004) GABAergic modulation of 5-HT7 receptor-mediated effects on 5-HT efflux in the guinea-pig dorsal raphe nucleus. Neuropharmacology 46: 935-941.
18. Gasbarri A, Cifariello A, Pompili A, Meneses A, (2008) Effect of 5-HT7 antagonist SB-269970 in the modulation of working and reference memory in the rat. Behav Brain Res 195: 164-170.
19. Meneses A, (2004) Effects of the 5-HT7 receptor antagonists SB-269970 and DR 4004 in autoshapingPavlovian/instrumental learning task. Behav Brain Res 155: 275-282.
20. Chudasama Y, Muir JL, (1997) Abehavioural analysis of the delayed non-matching to position task: the effects of scopolamine, lesions of the fornix and of the prelimbic region on mediating behaviours by rats. Psychopharmacology 134: 73-82.
21. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, et al. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214.
22. Moghaddam B, Adams B, Verma A, Daly D, (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17: 2921-2927.
23. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, et al. (2003) NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology 169: 215-233.
24. Stefani MR, Moghaddam B, (2005) Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia. Biol Psychiatry 57: 433-436.
25. Kristiansen LV, Huerta I, Beneyto M, Meador-Woodruff JH, (2007) NMDA receptors and schizophrenia. CurrOpinPharmacol 7: 48-55.
26. Adams B, Moghaddam B, (1998) Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 18: 5545-5554.
27. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA, (2003) Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117: 697-706.
28. Lopez-Gil X, Babot Z, Amargos-Bosch M, Sunol C, Artigas F, et al. (2007) Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology 32: 2087-2097.
29. Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, Arnsten AF, (2007) Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nature Neurosci 10: 376-384.
30. Hagan JJ, Price GW, Jeffrey P, Deeks NJ, Stean T, et al. (2000) Characterization of SB-269970-A, a selective 5-HT(7) receptor antagonist. Br J Pharmacol 130: 539-548.
31. Paxinos G, Watson C, (1997) The Rat Brain in Stereotaxic Coordinates. San Diego Academic Press.
32. Uslaner JM, Smith SM, Huszar SL, Pachmerhiwala R, Hinchliffe RM, et al. T-type calcium channel antagonism produces antipsychotic-like effects and reduces stimulant-induced glutamate release in the nucleus accumbens of rats. Neuropharmacology In Press.
33. Barbier AJ, Aluisio L, Lord B, Qu Y, Wilson SJ, et al. (2007) Pharmacological characterization of JNJ-28583867, a histamine H3 receptor antagonist and serotonin reuptake inhibitor. Eur JPharmacol 576: 43-54.
34. Perez-Garcia GS, Meneses A, (2005) Effects of the potential 5-HT7 receptor agonist AS 19 in an autoshaping learning task. Behavioural Brain Research 163: 136-140.
35. Stahl SM, (2010) The serotonin-7 receptor as a novel therapeutic target. J ClinPsychiatry 71: 1414-1415.
36. Perez-Garcia G, Gonzalez-Espinosa C, Meneses A, (2006) An mRNA expression analysis of stimulation and blockade of 5-HT7 receptors during memory consolidation. Behav Brain Res 169: 83-92.
37. Galici R, Boggs JD, Aluisio L, Fraser IC, Bonaventure P, et al. (2009) JNJ-10181457, a selective non-imidazole histamine H3 receptor antagonist, normalizes acetylcholine neurotransmission and has efficacy in translational rat models of cognition. Neuropharmacology 56: 1131-1137.
38. Dunnett SB, (1985) Comparative effects of cholinergic drugs and lesions of nucleus basalis or fimbria-fornix on delayed matching in rats. Psychopharmacology 87: 357-363.
39. Robinson JK, Mao JB, (1997) Differential effects on delayed non-matching-to-position in rats of microinjections of muscarinic receptor antagonist scopolamine or NMDA receptor antagonist MK-801 into the dorsal or ventral extent of the hippocampus. Brain Res 765: 51-60.
40. Doyle KM, Feerick S, Kirkby DL, Eddleston A, Higgins GA, (1998) Comparison of various N-methyl-D-aspartate receptor antagonists in a model of short-term memory and on overt behaviour. BehavPharmacol 9: 671-681.
41. Horiguchi M, Meltzer H, (2010) 5-HT7 Receptor Antagonism Contributes to the Ability of Atypical Antipsychotic Drugs (APDs), Including Lurasidone and Amisulpride, to Reverse the Phencyclidine (PCP)-induced Deficit in Novel Object Recognition in Rats. Neuropsychopharmacology 35.
42. Horisawa T, Ishibashi T, Nishikawa H, Enomoto T, Toma S, et al. The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: Mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone. Behav Brain ResIn Press.
43. Ballaz SJ, Akil H, Watson SJ, (2007) The 5-HT7 receptor: Role in novel object discrimination and relation to novelty-seeking behavior. Neuroscience 149: 192-202.
44. Smith SM, Pachmerhiwala R, Hinchliffe RM, Yao L, (2010) Characterization of the central neurochemical effects of the mGluR2/3 receptor agonist LLY379268 and the psychostimulant MK-801. Brussels 13th International Conference on In Vivo Methods: Monitoring Molecules in Neuroscience.